Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Indian pharma sector to grow at 10-12 pc during FY19-22, says ICRA

      Indian pharma sector to grow at 10-12 pc during FY19-22, says ICRA

      Medical Dialogues Bureau19 Dec 2019 4:30 AM
      Icra, however, warned that while the US growth is expected to remain at high single-digit to low double-digit, it will face headwinds given the...
      Astellas, Seattle Genetics cancer drug Padcev gets speedy nod from USFDA

      Astellas, Seattle Genetics cancer drug Padcev gets speedy nod from USFDA

      Medical Dialogues Bureau19 Dec 2019 4:00 AM
      The drug, Padcev, is the first USFDA approved treatment in the United States for patients with advanced or metastatic urothelial cancer, Astellas...
      Biohaven Pharma acute migraine drug Vazegepant succeeds in study

      Biohaven Pharma acute migraine drug Vazegepant succeeds in study

      Medical Dialogues Bureau19 Dec 2019 3:45 AM
      Vazegepant is the first CGRP treatment delivered in an intranasal formulation, which benefits patients uncomfortable with needles, Biohaven Pharma...
      Purdue Pharma CEO bonus opposed by senators

      Purdue Pharma CEO bonus opposed by senators

      Medical Dialogues Bureau19 Dec 2019 3:29 AM
      "Purdue Pharma is still more concerned with motivating high-level employees to sell more drugs than it is with public health or helping states...
      Hetero launches HIV drug Taffic in India post DCGI nod

      Hetero launches HIV drug Taffic in India post DCGI nod

      Medical Dialogues Bureau18 Dec 2019 6:00 AM
      Hetero Lab's antiretroviral combination drug- Taffic is a generic version of Gilead's Biktarvy and has been approved by the Drug Controller General of...
      Lupin arm Nanomi BV completes Kyowa divestiture to Unison

      Lupin arm Nanomi BV completes Kyowa divestiture to Unison

      Medical Dialogues Bureau18 Dec 2019 4:15 AM
      "The transaction generates post-tax net cash inflow of nearly 33,429 million Japanese yen (about Rs 2,158 crore) and significantly strengthens Lupin's...
      GSK seeks USFDA nod for myeloma drug Belantamab Mafodotin

      GSK seeks USFDA nod for myeloma drug Belantamab Mafodotin

      Medical Dialogues Bureau18 Dec 2019 3:55 AM
      The trial was testing GSK's experimental multiple myeloma drug Belantamab Mafodotin, also known as GSK2857916, in patients who had received four to...
      Bayer appeals to reverse USD 25 million Roundup verdict

      Bayer appeals to reverse USD 25 million Roundup verdict

      Medical Dialogues Bureau18 Dec 2019 3:30 AM
      In a filing in the U.S. Court of Appeals for the 9th Circuit dated Friday, Bayer said the verdict defied regulatory findings and sound science, adding...
      Indian trademark rights, brand for anti-diabetic drug Vildagliptin acquired by Cipla

      Indian trademark rights, brand for anti-diabetic drug Vildagliptin acquired by Cipla

      Medical Dialogues Bureau17 Dec 2019 8:44 AM
      Cipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin), the company...
      Indoco Remedies Goa plant gets GMP certificate from UK health regulator

      Indoco Remedies Goa plant gets GMP certificate from UK health regulator

      Medical Dialogues Bureau17 Dec 2019 4:00 AM
      This is an outcome of the last successful inspection conducted by UK Medicines and Healthcare Products Regulatory Agency (MHRA) from September 16-20...
      Pfizer, Astellas Pharma get USFDA nod for prostate cancer therapy Xtandi

      Pfizer, Astellas Pharma get USFDA nod for prostate cancer therapy Xtandi

      Medical Dialogues Bureau17 Dec 2019 3:45 AM
      Pfizer said Xtandi, in combination with an anti-hormone therapy, reduced the risk of cancer spreading or deaths by 61% in men with the disease,...
      Roche wins US antitrust nod for USD 4.3 billion deal to buy Spark Therapeutics

      Roche wins US antitrust nod for USD 4.3 billion deal to buy Spark Therapeutics

      Medical Dialogues Bureau17 Dec 2019 3:42 AM
      The FTC approved the deal, which was originally announced in February, without requiring any asset sales to ensure that the planned merger complies...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok